Auroma Life Science Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 29-07-2024
- Paid Up Capital ₹ 1.13 M
as on 29-07-2024
- Company Age 21 Year, 16 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 29-07-2024
- Revenue -2.24%
(FY 2023)
- Profit 43.91%
(FY 2023)
- Ebitda 180.37%
(FY 2023)
- Net Worth 17.27%
(FY 2023)
- Total Assets 16.91%
(FY 2023)
About Auroma Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 1.13 M.
The company currently has active open charges totaling ₹2.00 M.
Ankurkumar Bhalodiya and Krushnakant Bhalodia serve as directors at the Company.
- CIN/LLPIN
U24231GJ2003PTC043309
- Company No.
043309
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Auroma Life Science?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krushnakant Bhalodia  | Additional Director | 21-Jan-2022 | Current |
| Ankurkumar Bhalodiya | Director | 28-Mar-2017 | Current |
Financial Performance of Auroma Life Science.
Auroma Life Science Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.24% decrease. The company also saw a substantial improvement in profitability, with a 43.91% increase in profit. The company's net worth Soared by an impressive increase of 17.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auroma Life Science?
In 2023, Auroma Life Science had a promoter holding of 100.00%. The company had 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zeon Biotech Private LimitedActive 6 years 8 monthsAnkurkumar Bhalodiya and Krushnakant Bhalodia are mutual person
Bombay Generics Private LimitedActive 35 years 6 monthsAnkurkumar Bhalodiya and Krushnakant Bhalodia are mutual person
Aplus Engitech LlpActive 7 years 5 monthsAnkurkumar Bhalodiya and Krushnakant Bhalodia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Apr 2022 | ₹2.00 M | Open |
How Many Employees Work at Auroma Life Science?
Unlock and access historical data on people associated with Auroma Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auroma Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auroma Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
